Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sinovac Biotech's share price for the quarter that ended in Jun. 2023 was $6.47. Sinovac Biotech's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 99.5 Mil. Therefore, Sinovac Biotech's market cap for the quarter that ended in Jun. 2023 was $643.8 Mil.
Sinovac Biotech's quarterly market cap
stayed the same
from Jun. 2022 ($643.8 Mil) to Dec. 2022 ($643.8 Mil) and
stayed the same
from Dec. 2022 ($643.8 Mil) to Jun. 2023 ($643.8 Mil).
Sinovac Biotech's annual market cap
increased
from Dec. 2020 ($642.4 Mil) to Dec. 2021 ($643.8 Mil) but then
stayed the same
from Dec. 2021 ($643.8 Mil) to Dec. 2022 ($643.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sinovac Biotech's Enterprise Value for Today is $-6,773.0 Mil.
Sinovac Biotech Market Cap Historical Data
The historical data trend for Sinovac Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sinovac Biotech's Market Cap
For the Biotechnology subindustry, Sinovac Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinovac Biotech's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Sinovac Biotech's Market Cap falls into.
Sinovac Biotech Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sinovac Biotech's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinovac Biotech (NAS:SVA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sinovac Biotech Market Cap Related Terms
Thank you for viewing the detailed overview of Sinovac Biotech's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Sinovac Biotech (Sinovac Biotech) Business Description
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SVA has been successfully added to your 